US equities
|
SPCX
$168.17
▲+5.79%
NVDA
$237.26
▲+1.41%
MU
$1,064.70
▼-0.95%
TSLA
$378.50
▲+2.13%
MSFT
$526.04
▲+1.64%
INTC
$116.92
▼-2.02%
SNDK
$1,720.68
▲+0.04%
META
$745.38
▲+2.38%
SPCX
$168.17
▲+5.79%
NVDA
$237.26
▲+1.41%
MU
$1,064.70
▼-0.95%
TSLA
$378.50
▲+2.13%
MSFT
$526.04
▲+1.64%
INTC
$116.92
▼-2.02%
SNDK
$1,720.68
▲+0.04%
META
$745.38
▲+2.38%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Zenas BioPharma, Inc. - Common Stock
(NQ:
ZBIO
)
28.13
-0.17 (-0.60%)
Delayed Quote
Updated: 11:06 AM EDT, Oct 5, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Zenas BioPharma, Inc. - Common Stock
< Previous
1
2
3
4
5
Next >
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Zenas BioPharma, Inc. of Class Action Lawsuit and Upcoming Deadlines - ZBIO
April 21, 2025
From
Pomerantz LLP
Via
GlobeNewswire
Zenas BioPharma, Inc. Stockholder Notice: Robbins LLP Reminds Investors of the Class Action Lawsuit Against ZBIO
April 21, 2025
From
Robbins LLP
Via
GlobeNewswire
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Zenas BioPharma
April 20, 2025
From
Faruqi & Faruqi LLP
Via
GlobeNewswire
ROSEN, THE FIRST FILING FIRM, Encourages Zenas BioPharma, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – ZBIO
April 19, 2025
From
The Rosen Law Firm PA
Via
GlobeNewswire
Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 17, 2025
From
Zenas BioPharma
Via
GlobeNewswire
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Zenas BioPharma
April 17, 2025
From
Faruqi & Faruqi, LLP
Via
Business Wire
ZBIO INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Zenas BioPharma, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
April 17, 2025
From
Robbins Geller Rudman & Dowd LLP
Via
Business Wire
ZBIO Investors Have Opportunity to Lead Zenas BioPharma, Inc. Securities Fraud Lawsuit with the Schall Law Firm
April 16, 2025
From
The Schall Law Firm
Via
Business Wire
ZBIO INVESTOR NEWS: ROSEN, THE FIRST FILING FIRM, Encourages Zenas BioPharma, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – ZBIO
April 16, 2025
From
The Rosen Law Firm PA
Via
GlobeNewswire
EQUITY ALERT: Rosen Law Firm Files Securities Class Action Lawsuit Against Zenas BioPharma, Inc. – ZBIO
April 16, 2025
From
The Rosen Law Firm, P.A.
Via
Business Wire
Zenas BioPharma, Inc. Announcement: If You Have Suffered Losses in Zenas BioPharma, Inc. (NASDAQ: ZBIO), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
April 13, 2025
From
The Rosen Law Firm PA
Via
GlobeNewswire
Zenas BioPharma, Inc. Investor News: If You Have Suffered Losses in Zenas BioPharma, Inc. (NASDAQ: ZBIO), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
April 10, 2025
From
The Rosen Law Firm PA
Via
GlobeNewswire
Zenas BioPharma Appoints Haley Laken, Ph.D., as Chief Scientific Officer
April 07, 2025
Dr. Laken brings over 25 years of leadership experience in research, development operations, scientific assessment and strategy
From
Zenas BioPharma
Via
GlobeNewswire
Zenas BioPharma, Inc. Announcement: If You Have Suffered Losses in Zenas BioPharma, Inc. (NASDAQ: ZBIO), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
April 04, 2025
From
The Rosen Law Firm PA
Via
GlobeNewswire
Zenas BioPharma, Inc. Announcement: If You Have Suffered Losses in Zenas BioPharma, Inc. (NASDAQ: ZBIO), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
April 01, 2025
From
The Rosen Law Firm PA
Via
GlobeNewswire
Excelerate Energy, MediaAlpha And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
↗
April 01, 2025
Via
Benzinga
Why PVH Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket
↗
April 01, 2025
Via
Benzinga
Rosen Law Firm Encourages Zenas BioPharma, Inc. Investors to Inquire About Securities Class Action Investigation – ZBIO
March 20, 2025
From
The Rosen Law Firm, P.A.
Via
Business Wire
Zenas BioPharma Gains Outperform Rating From Analyst As Key Autoimmune Trials Progress
↗
March 20, 2025
Wedbush initiates coverage on Zenas BioPharma, citing strong potential for obexelimab in autoimmune diseases, with key clinical data expected in 2025 and 2026.
Via
Benzinga
Zenas BioPharma Appoints Lisa von Moltke, M.D., as Head of Research and Development and Chief Medical Officer
March 17, 2025
From
Zenas BioPharma
Via
GlobeNewswire
Zenas BioPharma Announces Key 2024 Accomplishments and 2025 Business Objectives to Support the Global Development and Commercialization of Therapies for Autoimmune Diseases
February 05, 2025
From
Zenas BioPharma
Via
GlobeNewswire
Zenas BioPharma to Present at the Guggenheim SMID Cap Biotech Conference
January 28, 2025
From
Zenas BioPharma
Via
GlobeNewswire
Progress Software, Disc Medicine And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
↗
January 22, 2025
Via
Benzinga
This Addus HomeCare Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
↗
December 16, 2024
Via
Benzinga
Visa To Rally Over 20%? Here Are 10 Top Analyst Forecasts For Wednesday
↗
December 11, 2024
Via
Benzinga
Zenas BioPharma Reports Third Quarter 2024 Financial Results and Provides Corporate Updates
November 12, 2024
From
Zenas BioPharma
Via
GlobeNewswire
Zenas BioPharma Completes Targeted Enrollment of the Phase 3 INDIGO Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD)
November 12, 2024
From
Zenas BioPharma
Via
GlobeNewswire
Zenas BioPharma to Participate in Upcoming Healthcare Investor Conferences
November 07, 2024
From
Zenas BioPharma
Via
GlobeNewswire
12 Health Care Stocks Moving In Friday's Intraday Session
↗
October 25, 2024
Via
Benzinga
StandardAero Surges In Market Debut
↗
October 06, 2024
Shares of StandardAero jumped 36% in the company's trading debut as the aircraft maintenance services provider raised $1.44 billion in its IPO. Additionally, Chain Bridge Bancorp opened on Oct. 5 at...
Via
Talk Markets
Topics
Initial Public Offering
< Previous
1
2
3
4
5
Next >
